Albert Koong: PFS of 10.3 month vs. 2.5 month in Pancreas Cancer patients with oligometastatic disease
Albert Koong, Division Head and Chair of the Department of Radiation Oncology at MD Anderson Cancer Center, shared on X:
“Congrats Ethan Ludmir and Chad Tang! This MD Anderson Cancer Center P2 randomized study shows PFS of 10.3 mo vs. 2.5 mo in Pancreas Cancer patients with oligometastatic disease treated with metastasis-directed therapy+systematic treatments vs. systematic treatments alone.”
Addition of Metastasis-Directed Therapy to Systemic Therapy for Oligometastatic Pancreatic Ductal Adenocarcinoma (EXTEND): A Multicenter, Randomized Phase II Trial
Autors: Ethan B. Ludmir, Alexander D. Sherry, Bryan M. Fellman, Suyu Liu, Tharakeswara Bathala, Cara Haymaker, Marina N. Medina-Rosales, Alexandre Reuben, Emma B. Holliday, Grace L.Smith, Sonal S. Noticewala, SarahNicholas, Tracy R. Price, Rachael M. Martin-Paulpeter, Luis A. Perles, Sunyoung S. Lee, Michael S. Lee, Brandon G. Smaglo, Ryan W. Huey, Jason Willis, Dan Zhao, Lorenzo Cohen, Cullen M. Taniguchi, Eugene J. Koay, Matthew H.G. Katz, Robert A. Wolff, Prajnan Das, Shubham Pant, Albert C. Koong, Chad Tang
Source: Albert Koong/X